BridgeBio Pharma (BBIO) Operating Expenses (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Operating Expenses data on file, last reported at $300.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 35.96% year-over-year to $300.5 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 33.92% YoY), and the FY2025 full-year result was $1.0 billion, up 25.85% from the prior year.
• Operating Expenses improved to $300.5 million in Q1 2026, from $293.7 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $300.5 million in Q1 2026 to a low of $128.0 million in Q1 2023.
• A 5-year average of $196.9 million and a median of $179.2 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses decreased 27.02% in 2023 and surged 64.68% in 2024, its largest moves.
• Tracing BBIO's Operating Expenses over 5 years: stood at $131.1 million in 2022, then soared by 36.66% to $179.2 million in 2023, then increased by 29.44% to $231.9 million in 2024, then increased by 26.66% to $293.7 million in 2025, then grew by 2.29% to $300.5 million in 2026.
• Business Quant data shows BBIO's Operating Expenses at $300.5 million in Q1 2026, $293.7 million in Q4 2025, and $265.9 million in Q3 2025.